Elinzanetant represents the next frontier in non-hormonal treatment for vasomotor symptoms.

How it works: Elinzanetant is a dual NK1/NK3 receptor antagonist. The NK3 receptor is found in the hypothalamus (the brain's thermostat). Blocking it reduces the abnormal thermoregulatory response that triggers hot flashes. The addition of NK1 blockade may offer additional benefits.

Clinical data: The phase 2 trial published in The Lancet (2024) showed statistically significant reductions in both frequency and severity of moderate-to-severe VMS. Phase 3 trials (OASIS 1, 2, and 3) are ongoing.

Potential advantages:

  • No hormone involvement — suitable for women who cannot take estrogen
  • Dual NK1/NK3 blockade may be more effective than NK3 alone
  • Phase 2 data suggests no need for liver monitoring (phase 3 will confirm)

Availability: As of July 2026, elinzanetant is not yet FDA or EMA approved. Phase 3 trials are expected to report results in 2027.

⚠️ This is a promising investigational treatment. Discuss with your specialist whether trial participation is appropriate for you.